ArticleNature communications2018
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 90 citations in OpenAlex.
- Long-Acting Therapeutics in Pediatric Health: Bridging Innovation and Access.Clinical pharmacology and therapeutics · 2026Review
- Long-Acting Antimalarial Drug Delivery Systems for Chemoprophylaxis: Formulation Strategies and Routes of Administration.Pharmaceutical research · 2026Review
- Ruthenium Complexes of Atovaquone Acting on Multiple Stages of theJournal of medicinal chemistry · 2026Article
- Combining seasonal malaria chemoprevention with novel therapeutics for malaria prevention: a mathematical modelling study.PLoS computational biology · 2026Article
- Comparative efficacy of free and PNAGA-encapsulated antimalarial drugs: temperature-dependent modulation ofFrontiers in pharmacology · 2026Article
- The synthesis of indomethacin prodrugs for the formation of nanosuspensions by emulsion templated freeze drying.RSC advances · 2025Article
- Orobanche aegyptiaca-chitosan nanocomposite efficacy against the freshwater snail Biomphalaria alexandrina.Scientific reports · 2025Article
- The Importance of Murine Models in Determining In Vivo Pharmacokinetics, Safety, and Efficacy in Antimalarial Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Long-acting intramuscular injections of ELQ-331, an antimalarial agent.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2024Article
- Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.Journal of materials chemistry. B · 2023Article
- Article
- Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito.Nature communications · 2023Article
- Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria Chemoprevention.The American journal of tropical medicine and hygiene · 2023Article
- Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023Review
- Unique Properties of Apicomplexan Mitochondria.Annual review of microbiology · 2023Review
- Atovaquone and Pibrentasvir Inhibit the SARS-CoV-2 Endoribonuclease and Restrict Infection In Vitro but Not In Vivo.Viruses · 2023Article
- Preliminary Assessment of Intramuscular Depot of Lipid-Based Decoquinate Formulation for Long-Term Chemoprophylaxis of Malaria.Pharmaceutics · 2022Article
- What Clinicians Need to Know About the Development of Long-Acting Formulations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- The risk of drug resistance during long-acting antimicrobial therapy.Proceedings. Biological sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Chemoprophylaxis is currently the best available prevention from malaria, but its efficacy is compromised by non-adherence to medication. Here we develop a long-acting injectable formulation of atovaquone solid drug nanoparticles that confers long-lived prophylaxis against Plasmodium berghei ANKA malaria in C57BL/6 mice. Protection is obtained at plasma concentrations above 200 ng ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.